|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||153.07 - 156.75|
|52 Week Range||90.75 - 236.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||211.07|
Futures Up on China-U.S. Trade Talks, China at New 52-Week Lows Washington sent an invitation to Beijing for trade talks in late August, and the Chinese have responded in kind. They plan to send their vice minister of commerce to discuss the situation, and U.S. futures are up on the news. Not so much for […] The post Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail appeared first on Market Exclusive.
Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
BeiGene (BGNE) is a clinical-stage biopharmaceutical company that develops molecularly targeted and immuno-oncology drugs for cancer. BeiGene also markets the drugs Abraxane, Revlimid, and Vidaza in China under its licensing agreement with Celgene (CELG).
Massachusetts-based gene therapy company bluebird bio – which is growing in Durham – has inked a $100 million deal for the development of treatments for cancer.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related ...
Regeneron Pharmaceuticals is investing $100 million in Bluebird Bio in an immuno-oncology collaboration that could rival the likes of Novartis and Gilead Sciences.
Stock futures opened in the red Monday, as chip stocks were active on analyst actions and Bluebird Bio surged on a development deal.
In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis. Orlissa (elagolix) is the first and only GnRH (gonadotropin-releasing hormone) antagonist approved for the treatment of moderate-to-severe endometriosis pain in women.
Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.
Right now, scientists are working in a cutting-edge field of medicine and health that is poised to mark a major demarcation point in human evolution. One of my favorite picks in this field is bluebird bio (NASDAQ:BLUE), a leader in the gene therapy revolution. It’s a standout because it encompasses gene therapy, cancer immunotherapy and gene editing in an effort to treat and cure a broad range of diseases.
Smaller biotechs are rising, following the announcement of a collaboration between bluebird bio (BLUE) and Regeneron Pharmaceuticals to tackle cancer and a double upgrade for Intercept Pharmaceuticals (ICPT). Bluebird bio (BLUE) is soaring on news that Regeneron Pharmaceuticals said it would make a $100 million investment in the biotech's stock at $238.10 a share, which represents a 59% premium over bluebird's Friday closing price. The two companies plan to collaborate on new immune cell therapies for cancer treatment over a period of five years. Bluebird is up 4.2% to $156.26 in recent trading, while Regeneron is falling 0.6% to $392.42. In addition, Intercept Pharmaceuticals (ICPT) was on the receiving end of a double upgrade from Goldman Sachs.
Shares of Bluebird Bio (BLUE) gained in morning trading Monday after the company announced a new partnership with Regeneron Pharmaceuticals (REGN). The five-year agreement will see both firms collaborate on new cell therapies for the treatment of cancer.
Bluebird bio Inc (NASDAQ: BLUE) shares were moving to the upside Monday after the announcement of a collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) in a bid to develop cell therapies for cancer. Regeneron and bluebird announced a collaboration to leverage their respective platforms to develop novel immune cell therapies for cancer. Immunotherapy uses the power of one's own immune system to combat cancer.
Bluebird Bio Inc. (BLUE) and Regeneron Pharmaceuticals Inc. (REGN) plan a five-year collaboration to develop new cell therapies for cancer, the companies announced early Monday. Regeneron will also invest $100 million in Bluebird Bio shares that values them at $238.10 per share, according to the announcement. Bluebird Bio shares rose 3.5% in morning trade, while Regeneron shares declined 0.3%.
Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and bluebird bio, Inc. (NASDAQ: BLUE) today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron's VelociSuite® platform technologies for the discovery and characterization of fully human antibodies as well as T cell receptors (TCRs) directed against tumor-specific proteins and peptides, and bluebird bio will contribute its field-leading expertise in gene transfer and cell therapy. "Like Regeneron, bluebird is a science-focused company looking to push the limits of what novel technologies can do in drug discovery and development," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.
bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies, as well as T cell receptors (TCRs) directed against tumor-specific proteins and peptides, and bluebird bio will contribute its field-leading expertise in gene transfer and cell therapy. “The collaboration with Regeneron complements bluebird bio’s growing immuno-oncology development portfolio, which includes clinical and pre-clinical CAR T and T cell receptor programs,” said Philip Gregory, D.Phil., Chief Scientific Officer of bluebird bio.
− Data Include Updates from Phase 2/3 Starbeam Study of Lenti-D for Cerebral Adrenoleukodystrophy and Initial Data from Ongoing Observational Study of Al
bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.
bluebird bio, Inc. (BLUE) today announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.m. ET at the Parker New York Hotel, New York City. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conference.